Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Ter Arkh ; 87(7): 77-87, 2015.
Article in Russian | MEDLINE | ID: mdl-26390729

ABSTRACT

UNLABELLED: aim: To study the factors influencing the results of treatment for candidemia (CE) in patients with blood system tumors. SUBJECTS AND METHODS: The investigation enrolled patients with hemoblastoses and CE. 30-day all-cause mortality was analyzed. RESULTS: In an 8-year period (2006-2013), CE was diagnosed in 55 patients (median age, 50 years); there was a preponderance of patients with lymphomas (47%) and acute leukemias (27%). The causative agents of CE were C. albicans (38%), C. parapsilosis (17%), C. krusei (11%), C. guilliermondii (11%), C. lusitaniae (6%), C. tropicalis (6%), C. glabrata (3%), C. famata (3%), C. pelliculosa (3%), and C. kefyr (2%). 30-day all-cause mortality was 43.6%. Recovery was statistically significantly more frequently seen following removal of a central venous catheter (67% versus 13%; p=0.004; odds ratio (OR), 14); after use of an antifungal drug on day 1 of isolation of Candida spp. from blood cultures (62% versus 13%; p=0.01; OR, 12); and that of echocandin as a first-line agent (86% versus 42%; p=0.005; OR, 8.4). The poor predictors were septic shock (5% recovery rate versus 86% in the patients without this factor; p<0.0001; OR, 0.01), granulocytopenia (42% versus 88%; p=0.001; OR, 0.1); use of amphotericin B as a first-line drug (26% versus 71%; p=0.002; OR, 0.15); hemoblastosis recurrence or resistance (39% versus 73%; p=0.01; OR, 0.24). Multivariate analysis showed the positive impact of antifungal administration on day 1 of isolation of Candida spp. from blood cultures on treatment results (p=0.03; OR, 27). CONCLUSION: High mortality rates were noted in the patients with hemoblastoses and CE. The recovery rates were statistically significantly higher after use of echinocandin as a first-line agent, after that of an antifungal agent on day 1 of positive blood cultures, after removal of a central venous catheter, and hemoblastosis remission.


Subject(s)
Antifungal Agents/therapeutic use , Candida/isolation & purification , Candidemia/drug therapy , Hematologic Neoplasms/complications , Adolescent , Adult , Aged , Candidemia/complications , Candidemia/diagnosis , Female , Humans , Male , Microbial Sensitivity Tests , Middle Aged , Retrospective Studies , Risk Factors , Treatment Outcome , Young Adult
2.
Ter Arkh ; 85(11): 47-53, 2013.
Article in Russian | MEDLINE | ID: mdl-24432599

ABSTRACT

AIM: To study the etiology, clinical manifestations, risk factors, and results of treatment for candidemia (CE) in patients with blood system tumors. SUBJECTS AND METHODS: The investigation included the patients with CE and hemoblastoses treated at the Hematology Research Center, Ministry of Health of the Russian Federation, in 2006 to 2012. The diagnosis of CE was established according to the single isolation of Candida spp. from blood cultures and the presence of infection symptoms. RESULTS: Over 7 years, CE was diagnosed in 57 patients aged 17 to 77 years (median age 48 years). Among the patients with CE, there was a preponderance of those with lymphomas (54%) and acute leukemias (30%). The pathogens of CE were C. albicans (33%), C. guilliermondii (26%), C. parapsilosis (12%), C. krusei (8%), C. lusitaniae (5%), C. famata (4%), C. tropicalis (4%), C. glabrata (4%), and C. pelliculosa (4%). The major risk factors were polychemotherapy (85%), granulocytopenia (63%), mucosal Candida spp. colonization (82%), the presence of central venous catheter (CVC) (97%), antibiotics (100%), and glucocorticosteroids (70%). The infection occurred with the intake of an antifungal agent in 33% of the patients; 60% had concomitant infections of other etiology. Antifungal agents were given to 52 (91%) patients. Within 30 days after CE diagnosis, 20 (35%) patients died; of them 12 (60%) patients showed tumor progression concurrent with the infection. The cure rate for CE was significantly higher in the use of echinocandin as a first-line drug (92%), in complete or partial remission in hemoblastosis (90%), CVC removal (76%) and in the administration of an antifungal drug on day 1 of detection of positive blood cultures (75%). The cure rate was significantly lower when septic shock developed and a patient was transferred to an intensive care unit (15%), when amphotericin B was used as a first-line drug (45%), when granulocytopenia occurred (53%), or glucocorticoids were given (55%). CONCLUSION: Candida non-albicans constitute a high proportion among the pathogens of CE. A number of risk factors influencing survival rates in CE have been identified. It is crucial to use echinocandin as a first-line agent as soon as possible after isolation of Candida spp. from blood cultures.


Subject(s)
Antifungal Agents/therapeutic use , Candida/isolation & purification , Candidemia/drug therapy , Hematologic Neoplasms/complications , Adolescent , Adult , Aged , Candidemia/complications , Candidemia/epidemiology , Female , Follow-Up Studies , Hematologic Neoplasms/epidemiology , Humans , Incidence , Male , Middle Aged , Retrospective Studies , Russia/epidemiology , Treatment Outcome , Young Adult
3.
Tsitol Genet ; 27(6): 8-13, 1993.
Article in Russian | MEDLINE | ID: mdl-7520639

ABSTRACT

The cytofluorescent probing method has shown that the radiation action under sharp irradiation regime in experimental animals and chronic regime in people influences the level of synthetic processes in lymphocytes and granulocytes of peripheral blood, characterized by alpha-index (RNA/DNA). The correlation has been found between alpha-index, survivability, doses. alpha-Index can be used to estimate the radiation biological effects and radiosensitivity testing.


Subject(s)
Granulocytes/radiation effects , Lymphocytes/radiation effects , Occupational Exposure/adverse effects , Animals , DNA/biosynthesis , DNA/radiation effects , Dose-Response Relationship, Radiation , Fluorescent Dyes , Gamma Rays , Granulocytes/metabolism , Humans , Lymphocytes/metabolism , Male , Mice , Mice, Inbred CBA , RNA/biosynthesis , RNA/radiation effects , Radiation Tolerance , Rats , Time Factors , Whole-Body Irradiation/mortality
SELECTION OF CITATIONS
SEARCH DETAIL
...